The global idiopathic pulmonary fibrosis market size was valued at USD 4.54 billion in 2024 and is projected to reach from ...

Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said ...

Pirfenidone use in patients with idiopathic pulmonary fibrosis may be linked to a lower incidence of lung cancer. Learn more.

Idiopathic pulmonary fibrosis (IPF) is a progressive and life-threatening lung disease but several ASX companies are giving ...

Most online pulmonary rehabilitation videos are understandable but lack key disease-specific information for conditions other than COPD.

The following is a summary of "Quality of life in idiopathic pulmonary fibrosis in Latin American countries," published in ...

Reality TV star Katie Price gave a heart-wrenching update on her mother, Amy, who is battling idiopathic pulmonary fibrosis ...

Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, recently announced that its breakthrough drug candidate for idiopathic pulmonary ...

Pliant Therapeutics has scrapped its Phase IIb Beacon-IPF trial for bexotegrast in idiopathic pulmonary fibrosis (IPF), after ...

The following is a summary of "Supplemental oxygen therapy use among patients with fibrosing interstitial lung disease in the United States," published in the February 2025 issue of the Respiratory ...

The primary objective of the RC-0315 Phase 1b clinical study is to measure drug safety and tolerability. The study's exploratory objectives will assess the effect of RC-0315 on disease pathology, ...

The new chief medical officer of the Pulmonary Fibrosis Foundation speaks about patients in rural areas, research ...